Compare Alcon AG (ALC) vs iShares MSCI Singapore ETF (EWS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs iShares MSCI Singapore ETF — how do they compare? Alcon AG trades at $66.85 (market cap $32.69B), while iShares MSCI Singapore ETF trades at $30.99. The key difference: Alcon AG pays a 0.54% dividend while iShares MSCI Singapore ETF pays none, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | EWS | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $92.22 | $30.66 |
52-Week Low | $62.02 | $26.08 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
EWS, the iShares MSCI Singapore ETF, trades at $30.28, up 0.4% on the day, with a bullish technical signal driven by strong moving average alignment. The ETF offers a 3.97% dividend yield and is approaching its 2007 all-time high of $31.94, supported by Singapore's economic stability and financial sector strength. Recent news highlights focus on Singapore's AI initiatives and property market activity.
The outlook for EWS is positive, with potential upside to the $31.94 resistance level, but risks include concentrated holdings in financials and regional economic sensitivity. Investor sentiment is mixed, with some analysts advocating for diversification benefits while others caution on valuation after recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →
